Current stock page

Stock Analysis

Mineralys Therapeutics, Inc. (MLYS) Stock Analysis

Mineralys Therapeutics, Inc. (MLYS) stock analysis covering valuation, fundamentals, technical indicators, risk, AIQ Momentum, analyst catalysts, dividends, and the current AIQ Score.

MLYS Stock Analysis Summary

Mineralys Therapeutics, Inc. (MLYS) currently has an AIQ Score of 33/100, indicating a very bearish setup. Quality is the strongest factor at 44/100. Momentum is the weakest current factor at 23/100. Technical, fundamental, catalyst, dividend, and risk evidence should be read together at the latest market-close snapshot.

Updated Nov 13, 2026 · Market-close data

MLYS at a Glance

Crawlable current metrics from the latest market-close stock snapshot.

MetricCurrent
Price$15.33
AIQ Score33/100
Overall ViewVery Bearish
Technical Analysis ConsensusStrong Sell
Market Cap$1.36B
P/E Ratio (TTM)-3.52
Forward P/E—
EPS (Q3 FY2026)-$0.64
Revenue (Q3 FY2026)$0
Dividend Yield (TTM)0.00%
Beta1.54
Volume1.31M
52-week range$14.78-$47.00
RSI 1432.05
50-Day SMA$22.66
200-Day SMA$26.16
Analyst Price Target$29.00
Next EarningsMar 11, 2027
As of Nov 13, 2026 · Market close

MLYSMineralys Therapeutics, Inc.

Healthcare / Biotechnology

Low Priority

In Line With Peers

Very BearishEdge 5/10
$15.33−$0.17 (−1.10%)

Latest quote

  • Momentum
    23
  • Value
    —
  • Quality
    44
  • Risk resilience
    35
  • Sentiment
    —
algovestiq.comScore data as of Nov 13, 2026

MLYS Stock Analysis Summary

Mineralys Therapeutics, Inc. (MLYS) currently has an AIQ Score of 33/100, indicating a very bearish setup. Quality is the strongest factor at 44/100. Momentum is the weakest current factor at 23/100. Technical, fundamental, catalyst, dividend, and risk evidence should be read together at the latest market-close snapshot.

Updated Nov 13, 2026 · Market-close data
AIQ Composite Posture: Very Bearish

In a very bearish regime, MLYS has AIQ Score of 33/100 with Quality base of 44/100 and fading Momentum at 23/100. Wait for component alignment before adding exposure.

Signal Conflict Detected

Quality (44/100) leads while Momentum (23/100) lags. This cross-factor spread creates entry timing uncertainty.

Healthcare · -1.10% stock move · MLYS classified in Biotechnology.

Current Evidence

Very BearishMLYS is in a very bearish AIQ regime; Quality is the strongest visible factor at 44/100.
Core coverage reflects visible evidence only

AlgovestIQ Evidence Summary

Current consensus, supporting evidence, recent changes, and what would strengthen or weaken the view.

Is MLYS Bullish or Bearish Right Now?

MLYS currently has a very bearish overall setup. Quality is the strongest factor at 44/100, while Momentum is weakest at 23/100. The current evidence suggests a bearish setup.

Bull Case
  • - Analyst target implies +89.17% upside from the latest quote.
Bear Case
  • - Momentum is weak at 23/100.
  • - Risk Resilience is weak at 35/100.
  • - Price is -41.39% below its 200-day SMA.
  • - Technical consensus has more sell votes than buy votes (37 vs 4).

Current Consensus

MLYS's Technical Analysis Consensus is currently Strong Sell, with 4 buy, 5 neutral, and 37 sell votes. MLYS's 14-day RSI is 32.05, which places the stock in a weaker momentum range. MLYS's beta is 1.54, indicating greater market sensitivity than the broad market.

Signal Confidence
High agreement

What Changed in MLYS?

The largest recent change in MLYS is Risk Resilience moving up by 2.0 points over the available 7-day comparison window. Quality remains the strongest visible factor.

AIQ Score
+0.0
Momentum
-1.0
Quality
+0.0
Risk
+2.0

What Would Change the MLYS Outlook?

The current very bearish outlook could improve if AIQ reaches 65 (Bullish), momentum recovers, earnings revisions strengthen, and price confirms a stronger trend above the 50-day and 200-day moving averages. It would weaken if AIQ falls below 50 (Bearish), price loses long-term moving-average support, analyst expectations deteriorate, or risk evidence worsens.

Bullish confirmation

AIQ 65+ (Bullish), RSI above 55, price above SMA-50/SMA-200, and positive catalyst or estimate-revision evidence.

Bearish deterioration

AIQ below 50 (Bearish), RSI below 45, loss of SMA-200, negative revisions, or rising volatility and drawdown risk.

MLYS Decision Framework

Public evidence layers, setup checks, and risk context for Mineralys Therapeutics, Inc..

Mineralys Therapeutics, Inc. (MLYS) Stock Analysis

Mineralys Therapeutics, Inc. has an AIQ Score of 33/100 in a Very Bearish regime. Quality is strongest at 44/100. Beta is 1.54, above market sensitivity. Review the supporting stock factors together before drawing a conclusion from any single score.

Evidence LayerPublic Evidence
Regime ContextMLYS is in a Very Bearish AIQ regime with score 33/100.
Signal ConflictThe primary conflict is that quality leads at 44/100 while momentum lags at 23/100.
Factor EvidenceMomentum 23/100 · Quality 44/100 · Risk 35/100
PersistenceCurrent snapshot evidence is shown; historical persistence remains in AIQ Pro.

Current Setup Checklist

Factor strengthFail

Quality is the strongest factor at 44/100.

TimingFail

Momentum is 23/100 and RSI (14) is 32.0.

Regime fitFail

MLYS is in a Very Bearish regime at 33/100.

Risk controlFail

Risk factor is 35/100 with beta 1.54 and annual volatility 61.66%.

ConflictWait

Current conflict: quality leads at 44/100 while momentum lags at 23/100.

AIQ Score
33/100
Price
$15.33
Beta
1.54
RSI (14)
32

MLYS Research Cluster

Ticker-specific paths for valuation, technical analysis, catalysts, dividends, financials, risk, and news.

MLYS Fundamentals

MLYS valuation, profitability, growth, margins, balance-sheet strength, and free cash flow.

Revenue
$0
Net income
-$57.33M
Free cash flow
-$43.1M
View full MLYS fundamental analysis

MLYS Technical Analysis

MLYS technical setup based on RSI, MACD, moving averages, AIQ Momentum, volume, trend, volatility, and pivots.

Technical Analysis Consensus
Strong Sell
RSI 14
32.05
Price vs SMA-50
-32.34%
View full MLYS technical analysis

MLYS Stock Catalysts

Track MLYS earnings, analyst ratings, price targets, estimate revisions, stock news, and upcoming events.

Next earnings
Mar 11, 2027
Analyst target
$29.00
News items
0
View MLYS earnings and stock catalysts

MLYS Dividend Analysis

MLYS dividend yield, annual dividend, payout ratio, payment history, and income reliability context.

Dividend yield
0.00%
Annual dividend
—
Payout ratio
—
View MLYS dividend history and analysis

MLYS Financial Data

MLYS revenue, earnings, income statement, balance sheet, cash flow, valuation ratios, and stock metrics.

Quarter revenue
$0
EPS
-$0.64
Periods
8
View MLYS financials

MLYS Risk Analysis

MLYS volatility, beta, drawdown, Sharpe ratio, VaR, and downside resilience.

Beta
1.54
Risk score
35/100
1Y volatility
61.66%
View MLYS risk analysis

MLYS Stock News

MLYS stock news, market tone, recent headlines, and catalyst context.

News items
0
Updated
—
Sentiment
—
Read MLYS stock news

MLYS vs Biotechnology Peers

Current peer cohort: MLYS · NAMS · NBIX · NKTR · NRIX. Compare AIQ, factor scores, Sharpe ratio and 1-year volatility in one indexable view.

PeerAIQValueMomentumRiskSharpe1Y VolatilityCompare
MLYS
Current stock
33/100—23/10035/100-1.4861.66%Current
NAMS
NewAmsterdam Pharma Company N.V.
41/10042/10022/10048/100-0.9153.82%MLYS vs NAMS
NBIX
Neurocrine Biosciences, Inc.
74/10077/10070/10069/1000.4935.22%MLYS vs NBIX
NKTR
Nektar Therapeutics
39/10047/10025/10041/100-0.1184.03%MLYS vs NKTR
NRIX
Nurix Therapeutics, Inc.
65/10094/10050/10040/1000.6467.30%MLYS vs NRIX
Pairwise Compare links: NAMS · NBIX · NKTR · NRIXMLYS vs NAMSMLYS vs NBIXMLYS vs NKTRMLYS vs NRIXCompare cohort

Peer cohort is resolved dynamically from the AlgovestIQ universe taxonomy and Compare relationship graph. Data as of Nov 13, 2026.

About the AIQ Score

Methodology for the current stock evidence.

As of Nov 13, 2026 · Market close

The AlgovestIQ AIQ Score combines multiple dimensions of stock evidence, including momentum, valuation exposure, quality, risk resilience, sentiment context, and timing signals. It is a descriptive research score, not a guarantee of future performance or a personalized recommendation.

View AIQ methodology

Factor Diagnostics

A compact bridge from the AIQ score to the evidence tabs.

Calculator
Calculate a MLYS stock return scenario

Open the return calculator with stock context while purchase price, shares, dates and fees remain user inputs.

Calculate stock return

Also for MLYS: historical return with reinvested dividends and stock average calculator for several buys.

AIQ Component Profile

Compare the five component scores on one consistent 0–100 scale.

Catalyst preview

Review earnings timing, revisions, news pressure, and prior event reactions in one place.

Open catalysts
Quarterly evidence

8 recent quarterly periods are available for review.

Checked Nov 16, 2026

AIQ Pro

Explore factor drivers, conflicts, persistence, and scenario sensitivity in the advanced workspace.

Fundamentals Verdict

Current snapshot fields are separate from reported-quarter statement tables.

Current TTM P/E
-3.52
As of Nov 13, 2026
Revenue growth
—
Gross margin
0.00%
Current debt / equity
0.2
Latest quarterly evidence

Latest period Sep 30, 2026.

Review fundamentals
Quarter revenue
$0
Quarter net income
-$57.33M
Quarter free cash flow
-$43.1M

Market Confirmation

Technicals are summarized first, with the indicator library behind it.

Trend
Bearish
Momentum
Bearish
RSI 14
32.05
MACD
-2.07

Risk Alignment

Higher resilience is stronger; exposure metrics stay separate.

Resilience
35/100
Beta
1.54
Annual volatility
61.66%
Max drawdown
-65.59%

MLYS Stock FAQ

What is MLYS stock price today?

Mineralys Therapeutics, Inc.'s current stock price is $15.33. Use the live quote with AIQ Score, news, and risk context rather than treating price alone as a decision signal.

Is MLYS bullish or bearish right now?

MLYS's bullish or bearish read depends on the current AIQ Score, factor alignment, technical analysis consensus, valuation, risk, and catalyst evidence. A mixed setup should be treated differently from a broad confirmation across those signals.

What is MLYS's market cap?

MLYS's market cap is $1.36B based on the latest completed market-close snapshot from Nov 13, 2026. Use it with P/E ratio, revenue, and growth metrics to frame company size, valuation, and peer comparisons.

What is MLYS's current P/E ratio?

MLYS's current P/E ratio is -3.52 based on the latest completed market-close snapshot from Nov 13, 2026. Read it with revenue growth, margins, EPS, cash flow, and peer valuation rather than using P/E alone.

What is MLYS's RSI?

MLYS's 14-day RSI is 32.05 based on the latest completed market-close snapshot from Nov 13, 2026. RSI should be interpreted with MACD, moving averages, volume, volatility, and price trend.

Is MLYS above its 50-day and 200-day moving averages?

MLYS is -32.34% from its 50-day SMA and -41.39% from its 200-day SMA based on the latest completed market-close snapshot from Nov 13, 2026. Moving-average position should be read with momentum and broader AIQ evidence.

When is MLYS's next earnings date?

MLYS's next earnings date is currently listed as Mar 11, 2027. Earnings can reset revenue, EPS, price target, analyst rating, and catalyst expectations.

Does MLYS pay a dividend?

MLYS's dividend yield is 0.00% based on the latest completed market-close snapshot from Nov 13, 2026. Dividend yield should be read with payout ratio, free cash flow, growth, and balance-sheet strength.